A new vaccine escape mutant of hepatitis B virus causes occult infection

Abstract

There is growing public concern regarding assay sensitivity to HBsAg mutants in clinical diagnosis and vaccine escape. The aim of this study is to introduce a new HBsAg mutant strain. The serum samples were those of patient X at the age of 3 months and 3 years respectively, and of her mother immediately before parturition, which were used to amplify the HBsAg-coding DNA fragments by PCR. The HBsAg DNA sequences were translated into their corresponding amino acid sequences and then aligned in pubmed with nucleotide blast. The sequencing data of S coding regions shows that patient X has been infected by a new HBV variant with an A to C substitution at nt431, resulting in an Asp(GAC)to Ala(GCC) substitution at aa144 of major protein; CC to AA substitution at nt359 and nt360, resulting in an Pro(CCC) to Gln(CAA) substitution at aa120 of pre “a” epitope; A to G substitution at nt491, resulting in an Glu(GAG) to Gly(GGG) substitution at aa164 of post “a” epitope. Three new mutations (S171F, S174N and Q181R) at the antigenic epitopes of HBV presented by HLA class I molecules are found. The HBV mutant strain causes vaccine escape and occult infection.

Abbreviations

WBC

white blood cell count

RBC

red blood cell count

Hb

hemoglobin

Plt

platelet count

CRP

C-reactive protein

TP

total protein

Alb

albumin

T-Bil

total bilirubin

AST

aspartate aminotransferase

ALT

alanine aminotransferase

ALP

alkaline phosphatase

γGTP

γ-glutamyl transferase

LDH

lactate dehydrogenase

UA

uric acid

AchE

acetylcholin esterase

TG

triglycerides

HBsAg

hepatitis B surface antigen

Anti-HBs

antibodies to HBsAg

Anti-HBc

antibodies to hepatitis B core antigen

HCV

hepatitis C virus

anti-HA

antibody to hepatitis A

EBV

Epstein-Barr virus

VCA

viral capsid antigen

EBNA

Epstein-Barr nuclear antigen

CMV

cytomegalovirus

EIA

enzyme immunoassay

Introduction

Hepatitis B virus (HBV) is an etiological agent of acute and chronic liver disease, including fatal fulminant hepatitis, cirrhosis and hepatocellular carcinoma, which is one of the most common human cancers and causes of death worldwide.¹ It has been estimated that more than 2 billion of the global population have been infected with HBV. Of these, approximately 360 million people are chronically infected, and an estimated 500,000 to 700,000 people die from complications of HBV infection each year worldwide.² Hepatitis B vaccination program has been implemented for decades and has obtained the remarkable achievements in reducing the incidence of HBV infection.^3,4 However, HBV has not gone away and always stay in a certain infection rate . The reason is very worthy of our thinking. In the article we introduce a new HBsAg mutant strain that genetic mutations occur in the area within and outside the `a' determinant region and the CTL epitope of HBsAg to clarify part of the possible mechanisms.

Case Report

Patient X, female, was born to a hepatitis B carriers’ mother. The patient had been immunized with HBV vaccine on a conventional 0, 1, 6 schedule: an injection of HBV vaccine was given at the time of birth, at 1 month and at 6 months of age. The serum samples used were those of patient X at the age of 3 months and 3 years respectively, and of her mother immediately before parturition.

Blood tests revealed negative results for HBsAg and positive results for HBeAg, anti-HBc and Pre-S1 in patient X’ sera at both the age of 3 months and 3 years. However, patient X’ HBV DNA is positive (6.2 × 10⁶ ge/ml). Her mother's blood test results revealed positive for HBsAg, anti-HBe and anti-HBc and negative for HBeAg and anti-HBs. The serum samples of her mother were taken immediately before parturition. A systematic blood sample of patient X analyzed at the age of 3 years revealed normal level liver enzymes (ALT: 38 U/L [upper normal limit <50], AST: 42 U/L [upper normal limit <55], ALP: 120 U/L [<136], γGTP: 11 U/L [<50] and T-Bil: 5.8 μmol/L [<19]) associated with normal level CRP: 2 mg/L [<8] with no leukocytosis. The detailed data was shown in Table 1. No history of hepatitis A, HCV, CMV and EBV infection were found in this patient as well. The clinical features of Patient X is characterized by poor drug effect, illness bounce after the drug was stopped, e antigen turns negative difficult.

Table 1.

Laboratory date of patient X at the age of 3 years

Test	Result	Units	Test	Result	Units	Test	Result	Units
WBC	4.39	×109 /L	TP	52.2	g/L	HBsAg	0.45 (−)	COI
RBC	3.6	×1012/L	Alb	33.3	g/L	anti-HBs	3.21 (−)	IU/L
Hb	112	g/L	T-Bil	5.8	μmol/L	HBeAg	1096.00 (+)	COI
PLT	179	×109 /L	AST	42	U/L	anti-HBe	7.36 (−)	COI
CRP	2	mg/L	ALT	38	U/L	anti-HBc	0.00 (+)	COI
			ALP	120	U/L	Pre-S1	35.4 (+)	s/co
			γGTP	11	U/L	HBV subtype	adw
			LDH	347	U/L	HBV genotype	B
			UA	193.9	μmol/L	anti-HCV	(−)
			AChE	8388	U/L	HCV-RNA	(−)
			TG	0.7	mmol/L	IgM anti-HA	(−)
			TC	2.73	mmol/L	EBV-VCA IgG/IgM	(−)
			CK	420	U/L	EBV EBNA	(−)
			CKMB	8	U/L	CMV IgG/IgM-EIA	(−)

The HBsAg-coding 1.2-kb fragments were amplified by PCR from the serum samples of patient X, who had failed to achieve protection from vaccination. The sequencing data of the S coding region shows that she has been infected by a new HBV variants with an A to C substitution at nt431, resulting in an Asp(GAC) to Ala(GCC) substitution at aa144 of major protein; CC to AA substitution at nt359 and nt360, resulting in an Pro(CCC) to Gln(CAA) substitution at aa120 of pre “a” epitope; A to G substitution at nt491, resulting in an Glu(GAG) to Gly(GGG) substitution at aa164 of post “a” epitope; C to T substitution at nt512, G to A substitution at nt522, A to G substitution at nt542, A to G substitution at nt227, resulting in an Ser(TCT) to Phe(TTT) substitution at aa171, an Ser(AGT) to Asn(AAT) substitution at aa174, an Gln(CAG) to Arg(CGG) substitution at aa181, an Tyr(TAT) to Cys(TGT) substitution at aa76, respectively. The detailed data was shown in Figure 1.

Figure 1.

The nucleotides sequence (nt) and amino acid (aa) sequence of S gene from patient X and her mother.The nucleotides sequence and amino acid sequences of S gene from patient X at the age of 3 months and 3 years are the same. All aa122 and aa160 among them are Lys(K), the characteristic amino acids for subtype adw.²²

Discussion

There is no difference in the sequences of HBV variants throughout the complete S region from the blood samples of patient X collected at her 3 months and 3 years of age respectively. This indicates that this variant is stable in maintaining persistent replication in the chronic patient. Comparing with the nucleotides sequence of S coding region of HBV DNA from the mother of patient X collected immediately before parturition, patient X shows distinctly differences in nt227, nt359, nt360, nt431, nt491, nt512, nt522 and nt542. Thus, patient X and her mother appear to be infected by 2 different HBV strains. Patient X turns out to be infected by a new mutant of HBV, mainly characterized by the immune escape.

The major HBsAg is the small molecule HBsAg with 226 amino acid residues. It has 2 moderately hydrophilic regions, one at residues 30 to 79 which is internal, and another at residues 99 to 168 which is exposed on the surface of the HBsAg particle. The second region, rich in cysteines and prolines, is considered as encompassing the immunogenic epitopes determining the serotypes of various HBV strains. Among them, the ‘a’ determinant is common to all HBV strains and is presumed to be important for the protective immune response to HBV. The domain between aa124 to aa147 is the critical region for neutralizing immunogenicity of the “a” determinant. Through the analysis of the sequence, we found patient X was infected by a new HBV variants with an A to C substitution at nt431, resulting in an Asp (GAC) to Ala (GCC) substitution at aa144 of the “a” determinant. Asp is an electropositive hydrophilic amino acid, but Ala is a neutral and hydrophobic one. The exchange between Asp and Ala should lead to a drastic change in the conformation of the “a” determinant, and in antigenicity as well. We believe this is one of the reasons why HBsAg cannot be detected by detection method based on the antibody. As Tyr (TAT) to Cys (TGT) substitution at aa76 is not exposed on the surface of the HBsAg particle, so this mutation on the new immune escape mutant of HBV will not affect antigenicity of HBsAg.

The region between aa100 and aa160 is termed as the major hydrophilic region (MHR). This comprises amino acids (aa) 99–160 that encompass the group-specific “a” determinant. The region between aa118 and aa123 was identified as a hot spot for insertion by investigators. The importance of an Pro(CCC) to Gln(CAA) substitution at aa120 of pre “a” epitope is that the mutations, situated closely adjacent to the ‘a’ determinant, could change the entire immunodominant region structure and therefore weaken the antigenicity even though no mutations were found within this ‘aa124-aa147’ region. In order to demonstrate the influence of adjacent residues on the ‘a’ determinant conformation, Scientists have done a lot of research. Mutation at the position of aa120 have been found to impair the performance of HBsAg tests, either alone or combination with other substitutions and the reported mutation phenotype at the position of aa120 is P120G/S/L.^5-8 It is the first time to our knowledge that the mutation that Pro (CCC) to Gln (CAA) substitution at aa120 has been reported.

Upstream (between 164 and 215) of MHR region of native and or recombinant surfance proteins has different binding capcities to antibodies.^9-11 Hence, the classical definition of the ‘a' immunodominant region may need to be extended to require adjacent amino acids supporting its conformation. The amino acid sequence of the polymerase between aa163 and aa210 is the region that can confer resistance to some polymerase inhibitors, when mutated.¹² We found an Glu(GAG) to Gly(GGG) substitution at aa164 of post “a” epitope of HBV on patient X and this may has important clinical significance.

The hepatitis B virus is not directly cytopathic for the infected hepatocyte, and it is generally presumed that viral clearance and liver cell injury during viral hepatitis are due to a CTL response to HBV encoded Ag presented by HLA class I molecules.^13,14 Schirmbeck et al. found that in H-2b mice even small changes in amino acid residues within 2 different CTL epitopes that mimic natural variants of adw2, ayr and adr, completely eliminated the immunogenicity of each epitope.¹³ A majority of mutations of up- and downstream of MHR in different studies were found to be potentially responsible for vaccine breakthrough and HBsAg undetectability which unpredictably were found to be located within the known CTL epitopes of surface protein.^15,16 Mutations that abrogate recognition of a viral epitope by class I-restricted CTL contribute to viral persistence in a subset of patients with chronic HBV infection who express a narrow repertoire of anti-HBV CTL responses. Thus, viral mutations in CTL epitopes were able to evade cellular immunity and contribute to persistency.^17-19 The aa 171–179 ^20,21 and aa175–184 ^22,23 is the antigenic epitopes of HBV presented by HLA class I molecules. In this region, we found 3 new mutations (S171F, S174N and Q181R) on HBV which infected patient X. Studies from our labora­tory have revealed there is a higher frequency of mutations at the position of the HLA-restricted CTL epitope of the surface gene in patients with chronic hepatitis B, suggesting that these mutations might contribute to chronic infections. In the process of clinical treatment, these variations have significantly affected patient X’ clinical treatment effect and disease outcome which is characterized by poor drug effect, illness bounce after the drug was stopped, e antigen turns negative difficultly.

In conclusion, the mutations of the new HBsAg variant that Asp (GAC) to Ala (GCC) substitution at aa144 of the “a” determinan and Pro (CCC) to Gln (CAA) substitution at aa120 causes false negative tests of HBsAg and vaccine escape; 3 new mutations (S171F, S174N and Q181R) on HBV from the pantient X induce CTL dysfunction contributing to chronic infections.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.